BIIL-260

• UNSPSC Description:

  BIIL-260 is a potent and long-acting orally active leukotriene B(4) receptor LTB4 antagonist, with anti-inflammatory activity. BIIL-260 interacts with the LTB4 receptor in a saturable, reversible, and competitive manner, has high affinity to the LTB4 receptor on isolated human neutrophil cell membranes with the Ki value of 1.7 nM[1].

• Target Antigen:

  Leukotriene Receptor

• Type:

  Reference compound

• Related Pathways:

  GPCR/G Protein

• Applications:

  COVID-19-immunoregulation

• Field of Research:

  Inflammation/Immunology

• Assay Protocol:

  https://www.medchemexpress.com/biil-260.html

• Smiles:

  N=C(N)C1=CC=C(C=C1)OCC2=CC=CC(COC3=CC=C(C=C3)C(C4=CC=C(C=C4)O)(C)C)=C2

• Molecular Weight:

  466.57

• References & Citations:

  [1]Birke FW, et al. In vitro and in vivo pharmacological characterization of BIIL 284, a novel and potent leukotriene B(4) receptor antagonist. J Pharmacol Exp Ther. 2001 Apr;297(1):458-66.

• Shipping Conditions:

  Room temperature

• Clinical Information:

  No Development Reported

• CAS Number:

  204974-93-6